Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
J Nutr ; 148(9): 1421-1425, 2018 09 01.
Article in English | MEDLINE | ID: mdl-30107536

ABSTRACT

Background: α-Cyclodextrin (α-CD), a soluble dietary fiber, may improve abnormal plasma lipids and promote weight loss. Preliminary evidence suggests that it may exert these effects by binding dietary fat and reducing absorption; this has not been tested in humans. Objective: The primary objective was to test whether supplemental α-CD increases fecal content of dietary lipid in humans. Methods: This was a randomized, double-blind, placebo-controlled, crossover study completed at the Mayo Clinic. Eight healthy volunteers, 5 premenopausal women and 3 men ages 23-54 y with body mass index (BMI; kg/m2) 18-27, underwent 2 separate study visits with a ≥2-wk washout period. The first morning of each visit volunteers consumed a standardized breakfast (14.5% protein, 27.5% fat, 60% carbohydrate, and 1.5 kcal/mL) containing [14C]tripalmitin and [3H]triolein with 2 g of α-CD or placebo, followed by 2 g of α-CD or placebo per meal for 2 more days. Volunteers consumed 100 g/d of dietary fat. Feces were collected for 72 h after the labeled breakfast to measure radiotracer content and total fecal fat. Radiotracer appearance in plasma TGs was measured at intervals after the labeled meal as a secondary outcome. Results: Virtually no 3H radiotracer, but an average of ∼20% of the 14C radiotracer was recovered in fecal lipids, with no difference between α-CD and placebo. Total fecal fat content and radiotracer appearance in postprandial plasma TGs did not differ between the α-CD and placebo treatments. Plasma appearance of 14C-TG was 37% ± 14% less (P < 0.0001) than 3H-TG. Conclusions: α-CD supplementation did not increase loss of dietary lipid in stool or total fecal fat compared with placebo in healthy adults. Greater stool loss and lesser appearance in plasma TGs of tripalmitin-derived [14C] compared with triolein-derived [3H] TGs imply different metabolic handling of these 2 dietary fat tracers. This trial was registered at www.clinicaltrials.gov as NCT03002168.


Subject(s)
Dietary Fats/pharmacokinetics , Feces/chemistry , alpha-Cyclodextrins/administration & dosage , Adult , Breakfast , Carbon Radioisotopes , Cross-Over Studies , Dietary Fats/analysis , Dietary Fats/metabolism , Dietary Fiber , Double-Blind Method , Female , Humans , Intestinal Absorption/drug effects , Male , Middle Aged , Placebos , Triglycerides/administration & dosage , Triglycerides/blood , Triglycerides/pharmacokinetics , Triolein/administration & dosage , Triolein/pharmacokinetics , Tritium , alpha-Cyclodextrins/metabolism
2.
Obesity (Silver Spring) ; 25(12): 2100-2107, 2017 12.
Article in English | MEDLINE | ID: mdl-28985040

ABSTRACT

OBJECTIVE: The relationship between inflammation, obesity, and adverse metabolic conditions is associated with adipose tissue macrophages (ATM). This study compared the measurements of human ATM using flow cytometry, immunohistochemistry (IHC), and real-time polymerase chain reaction (RT-PCR) of ATM markers. METHODS: A new software program (AMCounter) was evaluated to help measure ATM using IHC, and this was compared to flow cytometry and RT-PCR. RESULTS: IHC had good intraindividual reproducibility for total (CD68), proinflammatory (CD14), and anti-inflammatory (CD206) ATM. The AMCounter improved interreader agreement and was more time efficient. Flow cytometry had acceptable intraindividual reproducibility for the percentage of CD68+ cells that were CD14+ or CD206+ , but not for ATMs per gram of tissue. ATMs per gram of tissue was much greater using IHC than flow cytometry. The flow cytometry and IHC measures of ATM from the same biopsies were not correlated. There were statistically significant correlations between RT-PCR CD68 and IHC CD68, CD14, and CD206 ATMs per 100 adipocytes. Also of interest were statistically significant correlations between RT-PCR CD68 and IHC CD68, CD14, and adipose flow cytometry measures of CD68+ , CD68+ /CD14+ , and CD68+ /CD206+ ATMs per gram of tissue. CONCLUSIONS: The AMCounter software helps provide reproducible and efficient measures of IHC ATMs. Flow cytometry, IHC, and RT-PCR measures of adipose inflammation provide somewhat different information.


Subject(s)
Adipocytes/metabolism , Adipose Tissue/metabolism , Flow Cytometry/methods , Macrophages/metabolism , Obesity/metabolism , Real-Time Polymerase Chain Reaction/methods , Adipose Tissue/cytology , Adult , Female , Humans , Immunohistochemistry , Male , Obesity/pathology
3.
Am J Clin Nutr ; 105(6): 1552-1558, 2017 06.
Article in English | MEDLINE | ID: mdl-28424185

ABSTRACT

Background: Increased omega-3 (n-3) fatty acid consumption is reported to benefit patients with metabolic syndrome, possibly due to improved adipose tissue function.Objective: We tested the effects of high-dose, very-long-chain ω-3 fatty acids on adipose tissue inflammation and insulin regulation of lipolysis.Design: A double-blind, placebo-controlled study compared 6 mo of 3.9 g eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)/d (4.2 g total ω-3/d; n = 12) with a placebo (4.2 g oleate/d; n = 9) in insulin-resistant adults. Before and after treatment, the volunteers underwent adipose tissue biopsies to measure the total (CD68+), pro- (CD14+ = M1), and anti- (CD206+ = M2) inflammatory macrophages, crown-like structures, and senescent cells, as well as a 2-step pancreatic clamping with a [U-13C]palmitate infusion to determine the insulin concentration needed to suppress palmitate flux by 50% (IC50(palmitate)f).Results: In the ω-3 group, the EPA and DHA contributions to plasma free fatty acids increased (P = 0.0003 and P = 0.003, respectively), as did the EPA and DHA content in adipose tissue (P < 0.0001 and P < 0.0001, respectively). Despite increases in adipose and plasma EPA and DHA in the ω-3 group, there were no significant changes in the IC50(palmitate)f (19 ± 2 compared with 24 ± 3 µIU/mL), adipose macrophages (total: 31 ± 2/100 adipocytes compared with 33 ± 2/100 adipocytes; CD14+: 13 ± 2/100 adipocytes compared with 14 ± 2/100 adipocytes; CD206+: 28 ± 2/100 adipocytes compared with 29 ± 3/100 adipocytes), crown-like structures (1 ± 0/10 images compared with 1 ± 0/10 images), or senescent cells (4% ± 1% compared with 4% ± 1%). There were no changes in these outcomes in the placebo group.Conclusions: Six months of high-dose ω-3 supplementation raised plasma and adipose ω-3 fatty acid concentrations but had no beneficial effects on adipose tissue lipolysis or inflammation in insulin-resistant adults. This trial was registered at clinicaltrials.gov as NCT01686568.


Subject(s)
Adipose Tissue/metabolism , Dietary Supplements , Docosahexaenoic Acids/pharmacology , Eicosapentaenoic Acid/pharmacology , Insulin Resistance/physiology , Insulin/metabolism , Adipocytes/metabolism , Adipose Tissue/cytology , Adult , Antigens, CD , Antigens, Differentiation, Myelomonocytic , Docosahexaenoic Acids/metabolism , Double-Blind Method , Eicosapentaenoic Acid/metabolism , Fatty Acids/blood , Fatty Acids/metabolism , Fatty Acids, Omega-3 , Female , Humans , Inflammation/metabolism , Lectins, C-Type , Lipolysis , Lipopolysaccharide Receptors , Macrophages/metabolism , Male , Mannose Receptor , Mannose-Binding Lectins , Metabolic Syndrome/metabolism , Middle Aged , Pancreas , Receptors, Cell Surface
4.
Adipocyte ; 5(1): 93-6, 2016.
Article in English | MEDLINE | ID: mdl-27144101

ABSTRACT

Adipose tissue fatty acid storage varies according to sex, adipose tissue depot and degree of fat gain. However, the mechanism(s) for these variations is not completely understood. We recently published findings based on the glycerol 3-phosphate acyltransferase (GPAT) enzyme activity assay we optimized for use with human adipose tissue. These findings include a decrease in total GPAT and GPAT1 as a function of adipocyte size in both omental and subcutaneous adipose tissue and a strong, positive correlations between ACS, GPAT, and DGAT activities for both sexes and depots and between these storage factors and palmitate storage rates into TAG. The aim of this commentary is to expand upon the data from our recent publication. We describe here additional details on the optimization of the GPAT enzyme activity assay, a correlation between DGAT and percentage palmitate in the diacylglycerol fraction, and sex differences in fatty acid storage factors and storage rates into TAG at high palmitate concentrations.

5.
Am J Physiol Endocrinol Metab ; 308(9): E830-46, 2015 May 01.
Article in English | MEDLINE | ID: mdl-25738782

ABSTRACT

Adipose tissue fatty acid storage varies according to sex, adipose tissue depot, and degree of fat gain. However, the mechanism(s) for these variations is not completely understood. We examined whether differences in adipose tissue glycerol-3-phosphate acyltransferase (GPAT) might play a role in these variations. We optimized an enzyme activity assay for total GPAT and GPAT1 activity in human adipose tissue and measured GPAT activity. Omental and subcutaneous adipose tissue was collected from obese and nonobese adults for measures of GPAT and GPAT1 activities, ex vivo palmitate storage, acyl-CoA synthetase (ACS) and diacylglycerol-acyltransferase (DGAT) activities, and CD36 protein. Total GPAT and GPAT1 activities decreased as a function of adipocyte size in both omental (r = -0.71, P = 0.003) and subcutaneous (r = -0.58, P = 0.04) fat. The relative contribution of GPAT1 to total GPAT activity increased as a function of adipocyte size, accounting for up to 60% of GPAT activity in those with the largest adipocytes. We found strong, positive correlations between ACS, GPAT, and DGAT activities for both sexes and depots (r values 0.58-0.91) and between these storage factors and palmitate storage rates into TAG (r values 0.55-0.90). We conclude that: 1) total GPAT activity decreases as a function of adipocyte size; 2) GPAT1 can account for over half of adipose GPAT activity in hypertrophic obesity; and 3) ACS, GPAT, and DGAT are coordinately regulated.


Subject(s)
Adipose Tissue/metabolism , Fatty Acids/metabolism , Glycerol-3-Phosphate O-Acyltransferase/metabolism , Adiposity , Adult , Aged , Female , Humans , Lipid Metabolism , Male , Middle Aged , Omentum/metabolism , Palmitic Acid/metabolism , Sex Factors , Subcutaneous Fat/metabolism , Triglycerides/metabolism
6.
Obesity (Silver Spring) ; 22(5): 1275-9, 2014 May.
Article in English | MEDLINE | ID: mdl-24639405

ABSTRACT

OBJECTIVE: Human adipocytes take up free fatty acids (FFA) directly from the circulation, even at times of high lipolytic activity. Whether these processes occurs simultaneously within the same cells or are partitioned between different cells, for example large and small cells, is unknown. METHODS: The direct FFA storage in subcutaneous fat in 13 adults were measured using a continuous infusion of [U-(13)C]palmitate and a bolus of [1-(14)C]palmitate followed 30 min later by abdominal and femoral adipose biopsies. The adipocytes were isolated by digestion procedures and separated into small, medium and large populations by differential floatation. RESULTS: Populations of adipocytes were isolated that were statistically and clinically (∼3 fold different) in size. Adipocyte lipid SA was not different between small, medium and large cells, therefore, FFA storage per unit lipid was not different. However, FFA storage rates were significantly (two to four times) greater per cell in large than small cells (P < 0.005). In summary, relative to lipid content, FFA storage rates are not different in large and small adipocytes, however, large cells have greater storage rates per cell. CONCLUSIONS: This suggests that the processes of FFA release and storage are taking place simultaneously in adipocytes.


Subject(s)
Adipocytes/metabolism , Fatty Acids, Nonesterified/metabolism , Adult , Body Mass Index , Female , Healthy Volunteers , Humans , Male , Palmitates/metabolism , Subcutaneous Fat/metabolism
7.
J Clin Endocrinol Metab ; 87(5): 2352-8, 2002 May.
Article in English | MEDLINE | ID: mdl-11994387

ABSTRACT

The symptoms and signs of Graves' ophthalmopathy (GO) result from both an accumulation of hydrated hyaluronan in the orbital muscles and connective tissues and an expansion of the orbital adipose tissues. Recent studies have suggested a link between the stimulation of adipogenesis within the orbit in GO and the expression in these tissues of TSH receptor (TSHR), the putative orbital autoantigen. To further investigate this association, we treated orbital fibroblasts from patients with GO with rosiglitazone, a thiazolidinedione agonist of the PPARgamma receptor that stimulates adipocyte differentiation. We found this compound to be a potent stimulator of functional TSHR expression as well as TSHR and PPARgamma mRNA levels in differentiated cultures. In addition, rosiglitazone treatment stimulated recruitment and differentiation of a subset of cells within these cultures into mature lipid-laden adipocytes. These results suggest that TSHR expression in GO orbital preadipocyte fibroblasts is linked to adipogenesis, and that ligation of the PPARgamma receptor results in differentiation of these cells. It is possible that endogenous PPARgamma ligands play a role in stimulating orbital adipogenesis in GO, and that future treatments may be aimed at antagonism of various components of the PPARgamma signaling system.


Subject(s)
Fibroblasts/metabolism , Graves Disease/metabolism , Graves Disease/pathology , Orbit/pathology , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Thyrotropin/metabolism , Stem Cells/metabolism , Thiazolidinediones , Transcription Factors/metabolism , Adipocytes/pathology , Cell Differentiation/drug effects , Cell Division/drug effects , Cells, Cultured , Fibroblasts/pathology , Humans , Orbit/metabolism , RNA, Messenger/metabolism , Receptors, Cytoplasmic and Nuclear/agonists , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Thyrotropin/drug effects , Receptors, Thyrotropin/genetics , Rosiglitazone , Stem Cells/pathology , Thiazoles/pharmacology , Transcription Factors/agonists , Transcription Factors/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...